{"entity":{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","aka":[],"tldr":"Pure-play viral vector CDMO that made lentiviral vector for Kymriah and manufactured the AstraZeneca COVID vaccine.","summary":"OXB, formerly Oxford Biomedica, based in Oxford and listed as OXB.L, is a pure-play viral vector CDMO that made the lentiviral vector for Kymriah and manufactured the AstraZeneca COVID vaccine. It offers lentiviral, AAV and adenoviral vector development and GMP manufacturing in the United Kingdom, in the United States at Bedford, and in France at the former ABL Europe sites. OnCo links it to viral vector manufacturing and to the CDMO term. Whether demand for lentiviral vector holds up as in vivo and non-viral approaches to CAR-T grow is the open question for its business. The viral vector manufacturing page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.oxb.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["viral-vector-manufacturing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cdmo"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oxford","country":"GB","companyType":"cro-services","website":"https://www.oxb.com","ticker":"OXB.L","investors":[],"funding":[]},"route":"/companies/oxford-biomedica/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/"}],"term":[{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/"}]}}